Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zodiac-Neo: Zolbetuximab + Durvalumab + FLOT Neoadjuvant Therapy in CLDN18.2-Positive Gastric/GEJ Cancer
jRCT2031260435Phase 2Recruiting
- Start
- Aug 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zolbetuximab, durvalumab, docetaxel, oxaliplatin, folinic acid and 1 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by none. Primary endpoint: Pathological complete response rate. Started Aug 2026; status: recruiting.
02
Drugs
zolbetuximabdurvalumabdocetaxeloxaliplatinfolinic acid
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031260435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260435.